← Eichor
Study identifier: NCT07038356 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Effects of Continued Administration of Empagliflozin in Patients With Heart Failure on Active SGLT2 Inhibitor Treatment Admitted for Acute Decompensated Heart Failure

Condition: Acute Decompensated Heart Failure (ADHF)  ·  Sponsor: Christian Schulze

PhasePhase 3
Planned participants536
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The goal of this clinical trial is to test the hypothesis that the continuation of empagliflozin during decongestive therapy in the setting of acute decompensated and hospitalized heart failure patients is not inferior compared to therapy cessation during the acute heart failure hospitalization. Randomized treatment (plus standard medical care) in patients with acute decompensated heart failure is one (1) tablet daily of empagliflozin 10 mg or matching placebo during the in-hospital stay (up to a maximum of 30 days), followed by treatment with empagliflozin 10 mg daily after discharge (but no later than day 31) until day 90. The primary outcome measure is the combined hierarchical endpoint of all-cause mortality, heart failure hospitalization and worsening renal function at 90 days after admission. Secondary outcome measures are the effects on urine output, diuretic efficiency, quality-of-life and the need for further administration of diuretics. Participants will * Take one tablet of study medication once daily (day 1 to day 90) * Restrict fluid intake to 1.5 liters of fluid per day and record the daily fluid intake for the study from day 1 to day 6 in the patient diary * Measure the urine output (day 1 to day 6) * Fill in Questionnaires (EQ-5D-3L (3-level version of the EuroQol five dimensional descriptive system), KCCQ-12 (Kansas City Cardiomyopathy Questionnaire comprising 12 items)) on day 0 (Baseline), at hospital discharge, and on day 30

This description comes directly from the study's public registry record.

Talk to the study team

Contact details are listed per location below or on the registry record.

Always discuss trial participation with your own doctor first.

Locations (9)

Jena University HospitalJena, Thuringia, GermanyRecruiting
Kerckhoff-Klinik GmbHBad Nauheim, GermanyRecruiting
Herzzentrum Dresden GmbH UniversitaetsklinikDresden, GermanyNot Yet Recruiting
Universitaetsmedizin GoettingenGöttingen, GermanyNot Yet Recruiting
Universitaetsklinikum Leipzig AöRLeipzig, GermanyRecruiting
Herzzentrum Leipzig GmbHLeipzig, GermanyNot Yet Recruiting
Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz KöRMainz, GermanyNot Yet Recruiting
LMU Klinikum Muenchen AöRMünchen, GermanyNot Yet Recruiting
Rostock University Medical CenterRostock, GermanyNot Yet Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07038356